HSP90AB1 and neoplasm: Furthermore, as was recently reported by Kühnel et al., combined therapeutic approach consisting of low concentrations of the HSP90 inhibitor NVP-AUY922 and knockdown of HSF1 using RNAi-Ready pSIRENRetroQ vectors significantly potentiated radiosensitization of tumor cells [62].